Assessment of neuroleptic-like properties of progesterone
There is considerable evidence from epidemiological studies that the onset of psychiatric disorders may be related to changes in the secretion of gonadal hormones. For example, the postpartum period appears to be a vulnerable phase for the occurrence of psychiatric disturbances such as dysphoric moo...
Gespeichert in:
Veröffentlicht in: | Psychopharmacology 1999-03, Vol.143 (1), p.29-38 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 38 |
---|---|
container_issue | 1 |
container_start_page | 29 |
container_title | Psychopharmacology |
container_volume | 143 |
creator | Rupprecht, R Koch, M Montkowski, A Lancel, M Faulhaber, J Harting, J Spanagel, R |
description | There is considerable evidence from epidemiological studies that the onset of psychiatric disorders may be related to changes in the secretion of gonadal hormones. For example, the postpartum period appears to be a vulnerable phase for the occurrence of psychiatric disturbances such as dysphoric mood and even severe psychotic disturbances. It has been suggested that a sudden drop in progesterone concentrations may contribute to the development of such disorders. Because the administration of this steroid might be of therapeutic value in psychiatric disturbances, we investigated the behavioral properties of progesterone in the rat to assess putative neuroleptic-like properties of this steroid. Progesterone administration dose-dependently increased the EEG activity during wakefulness in the 10- to 30-Hz frequency bands and decreased locomotor activity. While no anxiolytic activity could be detected in the plus maze, the highest dose of progesterone (90 mg/kg) exerted an inhibitory effect on the conditioned avoidance response. In contrast to haloperidol (0.5 mg/kg), progesterone neither produced catalepsy nor antagonized amphetamine-induced stereotypy. However, both progesterone (10, 30 and 90 mg/kg) and haloperidol (0.1 mg/kg) effectively restored the disruption of the prepulse inhibition (PPI) of the acoustic startle response (ASR) that was evoked by apomorphine (2 mg/kg). In contrast, allopregnanolone (10 mg/kg), one of the main metabolites of progesterone, did not significantly antagonize the effect of apomorphine on the PPI. This behavioral profile of progesterone is compatible with the sedative properties of its metabolite allopregnanolone via the GABAA receptor, but also with the possibility that progesterone itself shares some properties with atypical antipsychotics, which may be relevant for the development and treatment of psychotic disturbances. |
doi_str_mv | 10.1007/s002130050916 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_17577144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17577144</sourcerecordid><originalsourceid>FETCH-LOGICAL-p198t-5f6850610615076a054a78b9c9d3607b9b17d3219f736b69941e88c07b9075753</originalsourceid><addsrcrecordid>eNpdkMtLw0AQxhdRbK0evUpB8Bad2dfsHkupDyh40XNI0omk5mU2Ofjfu8V6cRgYPr4f8w0jxDXCPQLQQwCQqAAMeLQnYo5ayUQCyVMxB1AqUWjcTFyEsIdY2ulzMUOQkoBoLvwqBA6h4XZcduWy5Wnoau7Hqkjq6pOX_dD1PIwVh4Md1QeHkYeu5UtxVmZ14KvjXIj3x83b-jnZvj69rFfbpEfvxsSU1hmwGNsA2QyMzsjlvvA7ZYFynyPtlERfkrK59V4jO1ccHCBDRi3E3e_eGP41xfS0qULBdZ213E0hxUgRah3B23_gvpuGNt6WKkQiS8ZDpG6O1JQ3vEv7oWqy4Tv9e4n6AVykX-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3117767590</pqid></control><display><type>article</type><title>Assessment of neuroleptic-like properties of progesterone</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Rupprecht, R ; Koch, M ; Montkowski, A ; Lancel, M ; Faulhaber, J ; Harting, J ; Spanagel, R</creator><creatorcontrib>Rupprecht, R ; Koch, M ; Montkowski, A ; Lancel, M ; Faulhaber, J ; Harting, J ; Spanagel, R</creatorcontrib><description>There is considerable evidence from epidemiological studies that the onset of psychiatric disorders may be related to changes in the secretion of gonadal hormones. For example, the postpartum period appears to be a vulnerable phase for the occurrence of psychiatric disturbances such as dysphoric mood and even severe psychotic disturbances. It has been suggested that a sudden drop in progesterone concentrations may contribute to the development of such disorders. Because the administration of this steroid might be of therapeutic value in psychiatric disturbances, we investigated the behavioral properties of progesterone in the rat to assess putative neuroleptic-like properties of this steroid. Progesterone administration dose-dependently increased the EEG activity during wakefulness in the 10- to 30-Hz frequency bands and decreased locomotor activity. While no anxiolytic activity could be detected in the plus maze, the highest dose of progesterone (90 mg/kg) exerted an inhibitory effect on the conditioned avoidance response. In contrast to haloperidol (0.5 mg/kg), progesterone neither produced catalepsy nor antagonized amphetamine-induced stereotypy. However, both progesterone (10, 30 and 90 mg/kg) and haloperidol (0.1 mg/kg) effectively restored the disruption of the prepulse inhibition (PPI) of the acoustic startle response (ASR) that was evoked by apomorphine (2 mg/kg). In contrast, allopregnanolone (10 mg/kg), one of the main metabolites of progesterone, did not significantly antagonize the effect of apomorphine on the PPI. This behavioral profile of progesterone is compatible with the sedative properties of its metabolite allopregnanolone via the GABAA receptor, but also with the possibility that progesterone itself shares some properties with atypical antipsychotics, which may be relevant for the development and treatment of psychotic disturbances.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s002130050916</identifier><identifier>PMID: 10227077</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Acoustic startle response ; Amphetamines ; Animals ; Antipsychotic Agents - pharmacokinetics ; Antipsychotic Agents - pharmacology ; Antipsychotics ; Anxiety - psychology ; Apomorphine ; Avoidance behavior ; Avoidance Learning - drug effects ; Catalepsy ; Catalepsy - chemically induced ; Dextroamphetamine - pharmacology ; Dopamine Uptake Inhibitors - pharmacology ; Electroencephalography - drug effects ; Epidemiology ; Haloperidol ; Locomotor activity ; Male ; Mental disorders ; Motor Activity - drug effects ; Pregnanolone ; Pregnanolone - metabolism ; Progesterone ; Progesterone - pharmacokinetics ; Progesterone - pharmacology ; Psychosis ; Psychotropic drugs ; Rats ; Rats, Wistar ; Reflex, Startle - drug effects ; Sleep and wakefulness ; Startle response ; Stereotyped behavior ; Stereotyped Behavior - drug effects ; Steroids ; γ-Aminobutyric acid A receptors</subject><ispartof>Psychopharmacology, 1999-03, Vol.143 (1), p.29-38</ispartof><rights>Springer-Verlag Berlin Heidelberg 1999.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10227077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rupprecht, R</creatorcontrib><creatorcontrib>Koch, M</creatorcontrib><creatorcontrib>Montkowski, A</creatorcontrib><creatorcontrib>Lancel, M</creatorcontrib><creatorcontrib>Faulhaber, J</creatorcontrib><creatorcontrib>Harting, J</creatorcontrib><creatorcontrib>Spanagel, R</creatorcontrib><title>Assessment of neuroleptic-like properties of progesterone</title><title>Psychopharmacology</title><addtitle>Psychopharmacology (Berl)</addtitle><description>There is considerable evidence from epidemiological studies that the onset of psychiatric disorders may be related to changes in the secretion of gonadal hormones. For example, the postpartum period appears to be a vulnerable phase for the occurrence of psychiatric disturbances such as dysphoric mood and even severe psychotic disturbances. It has been suggested that a sudden drop in progesterone concentrations may contribute to the development of such disorders. Because the administration of this steroid might be of therapeutic value in psychiatric disturbances, we investigated the behavioral properties of progesterone in the rat to assess putative neuroleptic-like properties of this steroid. Progesterone administration dose-dependently increased the EEG activity during wakefulness in the 10- to 30-Hz frequency bands and decreased locomotor activity. While no anxiolytic activity could be detected in the plus maze, the highest dose of progesterone (90 mg/kg) exerted an inhibitory effect on the conditioned avoidance response. In contrast to haloperidol (0.5 mg/kg), progesterone neither produced catalepsy nor antagonized amphetamine-induced stereotypy. However, both progesterone (10, 30 and 90 mg/kg) and haloperidol (0.1 mg/kg) effectively restored the disruption of the prepulse inhibition (PPI) of the acoustic startle response (ASR) that was evoked by apomorphine (2 mg/kg). In contrast, allopregnanolone (10 mg/kg), one of the main metabolites of progesterone, did not significantly antagonize the effect of apomorphine on the PPI. This behavioral profile of progesterone is compatible with the sedative properties of its metabolite allopregnanolone via the GABAA receptor, but also with the possibility that progesterone itself shares some properties with atypical antipsychotics, which may be relevant for the development and treatment of psychotic disturbances.</description><subject>Acoustic startle response</subject><subject>Amphetamines</subject><subject>Animals</subject><subject>Antipsychotic Agents - pharmacokinetics</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotics</subject><subject>Anxiety - psychology</subject><subject>Apomorphine</subject><subject>Avoidance behavior</subject><subject>Avoidance Learning - drug effects</subject><subject>Catalepsy</subject><subject>Catalepsy - chemically induced</subject><subject>Dextroamphetamine - pharmacology</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Electroencephalography - drug effects</subject><subject>Epidemiology</subject><subject>Haloperidol</subject><subject>Locomotor activity</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Motor Activity - drug effects</subject><subject>Pregnanolone</subject><subject>Pregnanolone - metabolism</subject><subject>Progesterone</subject><subject>Progesterone - pharmacokinetics</subject><subject>Progesterone - pharmacology</subject><subject>Psychosis</subject><subject>Psychotropic drugs</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reflex, Startle - drug effects</subject><subject>Sleep and wakefulness</subject><subject>Startle response</subject><subject>Stereotyped behavior</subject><subject>Stereotyped Behavior - drug effects</subject><subject>Steroids</subject><subject>γ-Aminobutyric acid A receptors</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkMtLw0AQxhdRbK0evUpB8Bad2dfsHkupDyh40XNI0omk5mU2Ofjfu8V6cRgYPr4f8w0jxDXCPQLQQwCQqAAMeLQnYo5ayUQCyVMxB1AqUWjcTFyEsIdY2ulzMUOQkoBoLvwqBA6h4XZcduWy5Wnoau7Hqkjq6pOX_dD1PIwVh4Md1QeHkYeu5UtxVmZ14KvjXIj3x83b-jnZvj69rFfbpEfvxsSU1hmwGNsA2QyMzsjlvvA7ZYFynyPtlERfkrK59V4jO1ccHCBDRi3E3e_eGP41xfS0qULBdZ213E0hxUgRah3B23_gvpuGNt6WKkQiS8ZDpG6O1JQ3vEv7oWqy4Tv9e4n6AVykX-A</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Rupprecht, R</creator><creator>Koch, M</creator><creator>Montkowski, A</creator><creator>Lancel, M</creator><creator>Faulhaber, J</creator><creator>Harting, J</creator><creator>Spanagel, R</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19990301</creationdate><title>Assessment of neuroleptic-like properties of progesterone</title><author>Rupprecht, R ; Koch, M ; Montkowski, A ; Lancel, M ; Faulhaber, J ; Harting, J ; Spanagel, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p198t-5f6850610615076a054a78b9c9d3607b9b17d3219f736b69941e88c07b9075753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Acoustic startle response</topic><topic>Amphetamines</topic><topic>Animals</topic><topic>Antipsychotic Agents - pharmacokinetics</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotics</topic><topic>Anxiety - psychology</topic><topic>Apomorphine</topic><topic>Avoidance behavior</topic><topic>Avoidance Learning - drug effects</topic><topic>Catalepsy</topic><topic>Catalepsy - chemically induced</topic><topic>Dextroamphetamine - pharmacology</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Electroencephalography - drug effects</topic><topic>Epidemiology</topic><topic>Haloperidol</topic><topic>Locomotor activity</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Motor Activity - drug effects</topic><topic>Pregnanolone</topic><topic>Pregnanolone - metabolism</topic><topic>Progesterone</topic><topic>Progesterone - pharmacokinetics</topic><topic>Progesterone - pharmacology</topic><topic>Psychosis</topic><topic>Psychotropic drugs</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reflex, Startle - drug effects</topic><topic>Sleep and wakefulness</topic><topic>Startle response</topic><topic>Stereotyped behavior</topic><topic>Stereotyped Behavior - drug effects</topic><topic>Steroids</topic><topic>γ-Aminobutyric acid A receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rupprecht, R</creatorcontrib><creatorcontrib>Koch, M</creatorcontrib><creatorcontrib>Montkowski, A</creatorcontrib><creatorcontrib>Lancel, M</creatorcontrib><creatorcontrib>Faulhaber, J</creatorcontrib><creatorcontrib>Harting, J</creatorcontrib><creatorcontrib>Spanagel, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rupprecht, R</au><au>Koch, M</au><au>Montkowski, A</au><au>Lancel, M</au><au>Faulhaber, J</au><au>Harting, J</au><au>Spanagel, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of neuroleptic-like properties of progesterone</atitle><jtitle>Psychopharmacology</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>1999-03-01</date><risdate>1999</risdate><volume>143</volume><issue>1</issue><spage>29</spage><epage>38</epage><pages>29-38</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>There is considerable evidence from epidemiological studies that the onset of psychiatric disorders may be related to changes in the secretion of gonadal hormones. For example, the postpartum period appears to be a vulnerable phase for the occurrence of psychiatric disturbances such as dysphoric mood and even severe psychotic disturbances. It has been suggested that a sudden drop in progesterone concentrations may contribute to the development of such disorders. Because the administration of this steroid might be of therapeutic value in psychiatric disturbances, we investigated the behavioral properties of progesterone in the rat to assess putative neuroleptic-like properties of this steroid. Progesterone administration dose-dependently increased the EEG activity during wakefulness in the 10- to 30-Hz frequency bands and decreased locomotor activity. While no anxiolytic activity could be detected in the plus maze, the highest dose of progesterone (90 mg/kg) exerted an inhibitory effect on the conditioned avoidance response. In contrast to haloperidol (0.5 mg/kg), progesterone neither produced catalepsy nor antagonized amphetamine-induced stereotypy. However, both progesterone (10, 30 and 90 mg/kg) and haloperidol (0.1 mg/kg) effectively restored the disruption of the prepulse inhibition (PPI) of the acoustic startle response (ASR) that was evoked by apomorphine (2 mg/kg). In contrast, allopregnanolone (10 mg/kg), one of the main metabolites of progesterone, did not significantly antagonize the effect of apomorphine on the PPI. This behavioral profile of progesterone is compatible with the sedative properties of its metabolite allopregnanolone via the GABAA receptor, but also with the possibility that progesterone itself shares some properties with atypical antipsychotics, which may be relevant for the development and treatment of psychotic disturbances.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>10227077</pmid><doi>10.1007/s002130050916</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3158 |
ispartof | Psychopharmacology, 1999-03, Vol.143 (1), p.29-38 |
issn | 0033-3158 1432-2072 |
language | eng |
recordid | cdi_proquest_miscellaneous_17577144 |
source | MEDLINE; SpringerNature Journals |
subjects | Acoustic startle response Amphetamines Animals Antipsychotic Agents - pharmacokinetics Antipsychotic Agents - pharmacology Antipsychotics Anxiety - psychology Apomorphine Avoidance behavior Avoidance Learning - drug effects Catalepsy Catalepsy - chemically induced Dextroamphetamine - pharmacology Dopamine Uptake Inhibitors - pharmacology Electroencephalography - drug effects Epidemiology Haloperidol Locomotor activity Male Mental disorders Motor Activity - drug effects Pregnanolone Pregnanolone - metabolism Progesterone Progesterone - pharmacokinetics Progesterone - pharmacology Psychosis Psychotropic drugs Rats Rats, Wistar Reflex, Startle - drug effects Sleep and wakefulness Startle response Stereotyped behavior Stereotyped Behavior - drug effects Steroids γ-Aminobutyric acid A receptors |
title | Assessment of neuroleptic-like properties of progesterone |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T19%3A56%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20neuroleptic-like%20properties%20of%20progesterone&rft.jtitle=Psychopharmacology&rft.au=Rupprecht,%20R&rft.date=1999-03-01&rft.volume=143&rft.issue=1&rft.spage=29&rft.epage=38&rft.pages=29-38&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s002130050916&rft_dat=%3Cproquest_pubme%3E17577144%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3117767590&rft_id=info:pmid/10227077&rfr_iscdi=true |